lobucavir
Lobucavir is an antiviral drug that shows broad-spectrum activity against herpesviruses, hepatitis B and other hepadnaviruses, HIV/AIDS and cytomegalovirus. It initially demonstrated positive results in human clinical trials against hepatitis B with minimal adverse effects but was discontinued from further development following the discovery of increased risk of cancer associated with long-term use in mice. Although this carcinogenic risk is present in other antiviral drugs, such as zidovudine and ganciclovir that have been approved for clinical use, development was halted by Bristol-Myers Squibb, its manufacturer. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Nov 2, 1999 (NCT00002352)
Timeline
No events for the selected filters.
Chemistry & pharmacology
SMILES
Nc1nc(=O)c2ncn([C@@H]3C[C@H](CO)[C@H]3CO)c2[nH]1- Mol. weight
- 265.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLobucavir ↗
- ChEMBLCHEMBL23550 ↗
Also known as
- 2-amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-6h-purin-6-one
- 9-(2,3-bis-(hydroxymethyl)-1-cyclobutyl)guanine
- bms 180194
- bms-180194
- carbocyclic oxetanocin g
- c-oxt-g
- cyclobut-g
- lobucavir
- lobucavir
- lobucavir
- lobucavir
- sq 33054
- sq-33054
- sq 34514
- sq-34,514
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002352 | N/A | Nov 2, 1999 | Bristol-Myers Squibb |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 1999 |